NCT00119392 - Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

July 31, 2009

Study Completion Date

April 23, 2016

Conditions

B-cell Chronic Lymphocytic LeukemiaNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone LymphomaWaldenström Macroglobulinemia

Interventions

BIOLOGICAL

rituximab

Given IV

DRUG

cyclosporine

Given orally

DRUG

fludarabine phosphate

Given IV

DRUG

mycophenolate mofetil

Given orally

RADIATION

yttrium Y 90 ibritumomab tiuxetan

Given IV

PROCEDURE

peripheral blood stem cell transplantation

Undergo transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo transplantation

RADIATION

total-body irradiation

Undergo TBI

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER